ASCL is one of India's leading manufacturers of CPC Blue Crude, a key raw material for manufacturing other pigments, dyes, rubber chemicals and plastics. Since starting production in 2005, the company has witnessed a good off-take for its products wi... More
ICI is a 51% subsidiary of ICI Plc. Although the company operates in 12 product lines which includes paints, pharmaceuticals, rubber chemicals, textile auxiliaries and polyurethane. Paints contribute to over 18% of total sales for ICI Limited. In lin... More
ASAHI SONGWON | AKZO NOBEL | ASAHI SONGWON/ AKZO NOBEL |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 13.0 | 50.2 | 25.8% | View Chart |
P/BV | x | 1.5 | 10.5 | 14.6% | View Chart |
Dividend Yield | % | 1.2 | 1.0 | 128.8% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASAHI SONGWON Mar-19 |
AKZO NOBEL Mar-19 |
ASAHI SONGWON/ AKZO NOBEL |
5-Yr Chart Click to enlarge
|
||
High | Rs | 361 | 1,993 | 18.1% | |
Low | Rs | 135 | 1,471 | 9.2% | |
Sales per share (Unadj.) | Rs | 239.3 | 640.8 | 37.3% | |
Earnings per share (Unadj.) | Rs | 14.9 | 46.3 | 32.2% | |
Cash flow per share (Unadj.) | Rs | 21.6 | 60.6 | 35.5% | |
Dividends per share (Unadj.) | Rs | 3.00 | 24.00 | 12.5% | |
Dividend yield (eoy) | % | 1.2 | 1.4 | 87.3% | |
Book value per share (Unadj.) | Rs | 157.8 | 249.5 | 63.2% | |
Shares outstanding (eoy) | m | 12.27 | 45.54 | 26.9% | |
Bonus/Rights/Conversions | - | BB | - | ||
Price / Sales ratio | x | 1.0 | 2.7 | 38.3% | |
Avg P/E ratio | x | 16.6 | 37.4 | 44.5% | |
P/CF ratio (eoy) | x | 11.5 | 28.6 | 40.3% | |
Price / Book Value ratio | x | 1.6 | 6.9 | 22.6% | |
Dividend payout | % | 20.1 | 51.8 | 38.8% | |
Avg Mkt Cap | Rs m | 3,042 | 78,875 | 3.9% | |
No. of employees | `000 | 0.1 | 1.7 | 8.5% | |
Total wages/salary | Rs m | 94 | 2,656 | 3.5% | |
Avg. sales/employee | Rs Th | 20,390.3 | 17,217.7 | 118.4% | |
Avg. wages/employee | Rs Th | 653.5 | 1,567.0 | 41.7% | |
Avg. net profit/employee | Rs Th | 1,270.3 | 1,244.8 | 102.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 2,936 | 29,184 | 10.1% | |
Other income | Rs m | 0 | 422 | 0.1% | |
Total revenues | Rs m | 2,937 | 29,606 | 9.9% | |
Gross profit | Rs m | 395 | 3,424 | 11.5% | |
Depreciation | Rs m | 82 | 652 | 12.5% | |
Interest | Rs m | 52 | 45 | 114.9% | |
Profit before tax | Rs m | 262 | 3,149 | 8.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 7 | 0.0% | |
Tax | Rs m | 79 | 1,046 | 7.6% | |
Profit after tax | Rs m | 183 | 2,110 | 8.7% | |
Gross profit margin | % | 13.5 | 11.7 | 114.7% | |
Effective tax rate | % | 30.3 | 33.2 | 91.2% | |
Net profit margin | % | 6.2 | 7.2 | 86.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,420 | 14,102 | 10.1% | |
Current liabilities | Rs m | 770 | 8,845 | 8.7% | |
Net working cap to sales | % | 22.1 | 18.0 | 122.9% | |
Current ratio | x | 1.8 | 1.6 | 115.7% | |
Inventory Days | Days | 77 | 49 | 157.9% | |
Debtors Days | Days | 68 | 56 | 122.8% | |
Net fixed assets | Rs m | 1,515 | 5,470 | 27.7% | |
Share capital | Rs m | 123 | 456 | 26.9% | |
"Free" reserves | Rs m | 1,813 | 10,907 | 16.6% | |
Net worth | Rs m | 1,936 | 11,363 | 17.0% | |
Long term debt | Rs m | 177 | 29 | 611.4% | |
Total assets | Rs m | 3,091 | 20,979 | 14.7% | |
Interest coverage | x | 6.1 | 71.0 | 8.6% | |
Debt to equity ratio | x | 0.1 | 0 | 3,588.6% | |
Sales to assets ratio | x | 1.0 | 1.4 | 68.3% | |
Return on assets | % | 7.6 | 10.3 | 73.9% | |
Return on equity | % | 9.4 | 18.6 | 50.9% | |
Return on capital | % | 14.9 | 28.1 | 52.9% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 1,876 | 586 | 320.1% | |
Fx outflow | Rs m | 780 | 2,899 | 26.9% | |
Net fx | Rs m | 1,096 | -2,313 | -47.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 271 | 1,392 | 19.4% | |
From Investments | Rs m | -29 | 1,852 | -1.5% | |
From Financial Activity | Rs m | -242 | -3,600 | 6.7% | |
Net Cashflow | Rs m | 0 | -356 | 0.0% |
Indian Promoters | % | 62.3 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 73.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 9.7 | - | |
FIIs | % | 0.0 | 2.3 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 37.7 | 15.1 | 249.7% | |
Shareholders | 5,133 | 41,161 | 12.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASAHI SONGWON With: KANSAI NEROLAC SHALIMAR PAINTS BERGER PAINTS ASIAN PAINTS
Compare ASAHI SONGWON With: PPG IND. (US) AKZO NOBEL (Netherland)
Share markets in India are presently trading on a negative note. The BSE Sensex is trading up by 357 points, up 0.7% at 49,267 levels.
For the quarter ended December 2019, AKZO NOBEL has posted a net profit of Rs 770 m (up 27.5% YoY). Sales on the other hand came in at Rs 7 bn (down 7.2% YoY). Read on for a complete analysis of AKZO NOBEL's quarterly results.
For the quarter ended December 2019, ASAHI SONGWON has posted a net profit of Rs 35 m (down 13.5% YoY). Sales on the other hand came in at Rs 585 m (down 11.2% YoY). Read on for a complete analysis of ASAHI SONGWON's quarterly results.
For the quarter ended September 2019, AKZO NOBEL has posted a net profit of Rs 492 m (up 34.0% YoY). Sales on the other hand came in at Rs 6 bn (down 11.2% YoY). Read on for a complete analysis of AKZO NOBEL's quarterly results.
For the quarter ended September 2019, ASAHI SONGWON has posted a net profit of Rs 79 m (up 48.3% YoY). Sales on the other hand came in at Rs 716 m (down 14.7% YoY). Read on for a complete analysis of ASAHI SONGWON's quarterly results.
For the quarter ended June 2019, ASAHI SONGWON has posted a net profit of Rs 54 m (up 12.9% YoY). Sales on the other hand came in at Rs 818 m (up 6.9% YoY). Read on for a complete analysis of ASAHI SONGWON's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More